首页 > 最新文献

Hepatic Medicine : Evidence and Research最新文献

英文 中文
COVID-19 and the Liver: A Complex and Evolving Picture. 2019冠状病毒病与肝脏:一幅复杂而不断演变的图景。
IF 2.1 Pub Date : 2023-11-07 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S384172
Simon D Taylor-Robinson, Marsha Y Morgan

Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily attacks the respiratory system, other organs, such as the liver, are also affected. In this overview, the effects of SARS-CoV-2 infection on the liver in both healthy people and in those with pre-existing liver disease are documented; the relationship between coronavirus disease 19 (COVID-19) vaccination and liver injury is examined; the mechanism of SARS-CoV-2-associated liver injury is explored; and the long-term consequences of COVID-19 are delineated, both in people with and without pre-existing liver disease.

虽然严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)主要攻击呼吸系统,但肝脏等其他器官也会受到影响。在本综述中,记录了SARS-CoV-2感染对健康人群和已有肝病患者肝脏的影响;研究冠状病毒病(COVID-19)疫苗接种与肝损伤的关系;探索sars - cov -2相关肝损伤机制;并描述了COVID-19对患有和不患有肝脏疾病的人的长期后果。
{"title":"COVID-19 and the Liver: A Complex and Evolving Picture.","authors":"Simon D Taylor-Robinson, Marsha Y Morgan","doi":"10.2147/HMER.S384172","DOIUrl":"10.2147/HMER.S384172","url":null,"abstract":"<p><p>Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily attacks the respiratory system, other organs, such as the liver, are also affected. In this overview, the effects of SARS-CoV-2 infection on the liver in both healthy people and in those with pre-existing liver disease are documented; the relationship between coronavirus disease 19 (COVID-19) vaccination and liver injury is examined; the mechanism of SARS-CoV-2-associated liver injury is explored; and the long-term consequences of COVID-19 are delineated, both in people with and without pre-existing liver disease.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107591067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Confounders of Serum Phosphatidylethanol: Role of Red Blood Cell Turnover and Cirrhosis. 血清磷脂酰乙醇:红细胞周转和肝硬化的作用。
IF 2.1 Pub Date : 2023-11-01 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S420732
Marc Bartel, Vanessa Hofmann, Shijin Wang, Johannes Mueller, Tom R Sundermann, Sebastian Mueller

Purpose: Ethyl glucuronide (EtG), ethyl sulfate (EtS) and phosphatidylethanol (PEth) are considered specific direct biomarkers for detecting alcohol consumption. However, PEth, which is produced in red blood cells (RBC), varies considerably between patients for unknown reasons. We here studied various confounders of PEth elimination including fibrosis after alcohol withdrawal.

Patients and methods: EtG, EtS and PEth together with routine laboratory and clinical parameters were studied in 100 Caucasian heavy drinkers prior and after alcohol detoxification. In addition, fibrosis stage and degree of steatosis were assessed by transient elastography (Fibroscan, Echosens, Paris).

Results: All three biomarkers were highly correlated (0.61-0.72) with initial serum alcohol levels, but only PEth correlated with daily alcohol consumption. After alcohol withdrawal, PEth significantly decreased within 6.1 days from 1708 to 810 ng/mL (half-life varied from 1.6 to 15.2 days). Both levels of serum alcohol but also EtG and EtS were higher in patients with liver cirrhosis as compared to patients without fibrosis despite comparable alcohol consumption suggesting a decreased alcohol elimination in patients with cirrhosis. PEth was also elevated in cirrhosis but not significantly. In contrast, PEth elimination rate was significantly higher in patients with enhanced RBC turnover and signs of alcohol-mediated hemolytic anemia with elevated ferritin, LDH and increased mean corpuscular volume (MCV).

Conclusion: We here demonstrate that alcohol elimination is decreased in patients with liver cirrhosis. In patients with cirrhosis, PEth levels are both affected in opposite directions by enhanced red blood cell turnover and elevated alcohol levels. Our data have important implications for the use and interpretation of PEth in the clinical setting.

目的:葡萄糖醛酸乙酯(EtG)、硫酸乙酯(EtS)和磷脂酰乙醇(PEth)被认为是检测饮酒量的特异性直接生物标志物。然而,由于未知原因,红细胞(RBC)中产生的PEth在患者之间差异很大。我们在这里研究了PEth消除的各种混杂因素,包括酒精戒断后的纤维化。患者和方法:对100名高加索人重度饮酒者在酒精解毒前后的EtG、EtS和PEth以及常规实验室和临床参数进行了研究。此外,通过瞬态弹性成像(Fibroscan,Echosens,Paris)评估纤维化分期和脂肪变性程度。结果:所有三种生物标志物与初始血清酒精水平高度相关(0.61-0.72),但只有PEth与每日饮酒量相关。停酒后,PEth在6.1天内从1708 ng/mL显著降低至810 ng/mL(半衰期从1.6天至15.2天不等)。与没有纤维化的患者相比,肝硬化患者的血清酒精水平以及EtG和EtS水平都更高,尽管饮酒量相当,表明肝硬化患者的酒精消除减少。肝硬化患者PEth也升高,但不显著。相反,红细胞周转率升高、伴有铁蛋白、LDH升高和平均红细胞体积(MCV)增加的酒精介导的溶血性贫血症状的患者,PEth清除率显著较高。结论:我们证明肝硬化患者的酒精清除率降低。在肝硬化患者中,PEth水平受到红细胞周转增强和酒精水平升高的相反影响。我们的数据对临床环境中PEth的使用和解释具有重要意义。
{"title":"Confounders of Serum Phosphatidylethanol: Role of Red Blood Cell Turnover and Cirrhosis.","authors":"Marc Bartel, Vanessa Hofmann, Shijin Wang, Johannes Mueller, Tom R Sundermann, Sebastian Mueller","doi":"10.2147/HMER.S420732","DOIUrl":"https://doi.org/10.2147/HMER.S420732","url":null,"abstract":"<p><strong>Purpose: </strong>Ethyl glucuronide (EtG), ethyl sulfate (EtS) and phosphatidylethanol (PEth) are considered specific direct biomarkers for detecting alcohol consumption. However, PEth, which is produced in red blood cells (RBC), varies considerably between patients for unknown reasons. We here studied various confounders of PEth elimination including fibrosis after alcohol withdrawal.</p><p><strong>Patients and methods: </strong>EtG, EtS and PEth together with routine laboratory and clinical parameters were studied in 100 Caucasian heavy drinkers prior and after alcohol detoxification. In addition, fibrosis stage and degree of steatosis were assessed by transient elastography (Fibroscan, Echosens, Paris).</p><p><strong>Results: </strong>All three biomarkers were highly correlated (0.61-0.72) with initial serum alcohol levels, but only PEth correlated with daily alcohol consumption. After alcohol withdrawal, PEth significantly decreased within 6.1 days from 1708 to 810 ng/mL (half-life varied from 1.6 to 15.2 days). Both levels of serum alcohol but also EtG and EtS were higher in patients with liver cirrhosis as compared to patients without fibrosis despite comparable alcohol consumption suggesting a decreased alcohol elimination in patients with cirrhosis. PEth was also elevated in cirrhosis but not significantly. In contrast, PEth elimination rate was significantly higher in patients with enhanced RBC turnover and signs of alcohol-mediated hemolytic anemia with elevated ferritin, LDH and increased mean corpuscular volume (MCV).</p><p><strong>Conclusion: </strong>We here demonstrate that alcohol elimination is decreased in patients with liver cirrhosis. In patients with cirrhosis, PEth levels are both affected in opposite directions by enhanced red blood cell turnover and elevated alcohol levels. Our data have important implications for the use and interpretation of PEth in the clinical setting.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure? 严重急性呼吸系统综合征冠状病毒2型感染后肝功能障碍患者的预后:我们应该测量什么?
IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-12 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S371507
Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab

Aim: Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.

Methods: This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.

Results: The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.

Conclusion: COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.

目标:自2019年以来,新冠肺炎疫情在世界各地肆虐。在大流行的早期,注意到新冠肺炎的多种肝脏表现。我们的目的是对新冠肺炎感染的肝功能障碍及其结果进行分类。方法:这是一篇综述文章,基于PubMed和Medline数据库中的文献检索,详细介绍了新冠肺炎相关肝功能障碍的短期和长期结果。结果:新冠肺炎最常见的肝脏表现是天冬氨酸氨基转移酶(AST)为主的转氨酶升高。一旦新冠肺炎感染消退,转氨酶就会改善。此外,新冠肺炎胆道病、自身免疫性肝炎相关的新冠肺炎和新冠肺炎引发的内脏静脉血栓形成也是其他表现。与普通人群相比,已有肝病的患者,尤其是肝硬化患者,感染新冠肺炎的预后较差。肝脏检查的升高与严重的新冠肺炎感染有关。慢性肝病患者感染新冠肺炎的发病率和死亡率较高。在慢性肝病患者中,失代偿性肝硬化、肝细胞癌和酒精相关性肝病与新冠肺炎感染的严重程度和死亡率增加相关。在慢性病毒性肝炎和新冠肺炎感染患者中,必须考虑新冠肺炎抗病毒治疗与乙型肝炎/丙型肝炎药物之间的相互作用。新冠肺炎疫苗接种相关的肝功能障碍已有报道。结论:新冠肺炎将持续存在。新冠肺炎肝功能不全是严重新冠肺炎感染的信号。慢性肝病患者死于新冠肺炎的死亡率高于普通人群。重要的是要记住在新冠肺炎大流行期间吸取的教训,以便现在和将来照顾新冠肺炎患者。需要进一步的研究来记录发生肝功能障碍的新冠肺炎患者的长期结果。
{"title":"Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?","authors":"Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab","doi":"10.2147/HMER.S371507","DOIUrl":"10.2147/HMER.S371507","url":null,"abstract":"<p><strong>Aim: </strong>Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.</p><p><strong>Methods: </strong>This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.</p><p><strong>Results: </strong>The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.</p><p><strong>Conclusion: </strong>COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/39/hmer-15-185.PMC10578169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41234818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Integrated Bioinformatic Assay of Genetic Expression Features and Analyses of Traditional Chinese Medicine Specific Constitution Reveal Metabolic Characteristics and Targets in Steatosis of Nonalcoholic Fatty Liver Disease. 基因表达特征的生物信息学综合分析和中药特异性组成分析揭示了非酒精性脂肪肝脂肪变性的代谢特征和靶点。
IF 2.1 Pub Date : 2023-10-06 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S428161
Chunping Qiao, Chengying Gu, Song Wen, Yanju He, Sheng Yang, Xinge Feng, Yipeng Zeng

Purpose: In this study, our primary aim is to analyze the genetic expression feature and analyze specific Traditional Chinese medicine (TCM) constitution distribution in non-alcoholic fatty liver disease (NAFLD) and reveal the metabolic characteristic of NAFLD.

Materials and methods: For revealing genetic features, we obtained the gene expression data from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). The genetic data on NAFLD were analyzed by identifying differentially expressed genes (DEGs), associated pathways, co-expressed genetic networks, and gene set enrichment function. Concurrently, we assessed specific constitution distributions among local NAFLD patients through established TCM constitution models and determined the independent variable, including specific constitution to the NAFLD via the regression analyses.

Results: The analyses on GEO datasets showed that simple steatosis in NAFLD is strongly associated with HOMA-insulin resistance (HOMA-IR). Analyses of GEO datasets revealed significantly altered genetic expression profiles between NAFLD and normal populations. For TCM constitution analyses, we demonstrated a decline in yin-yang harmony (YYH) and yang-asthenia (YAAC) constitution, whereas there was an increase in qi-stagnation (QSC) and phlegm-dampness (PDC) in NAFLD. The binary logistic regression analysis indicated that besides other metabolic parameters, YYH, qi asthenia (QAC), YYAC, and yin-asthenia (YAC) were the independent variables of NAFLD, while YAC was the independent variables of T2D. The multilinear regression analyses suggested that NAFLD, DM, BMI, waist, TC, TG, hypertension, ALT, AST, and YAC were the significant determinators of the FPG.

Conclusion: This study presents a relatively comprehensive metabolic profile in steatosis of NAFLD, revealed by significant genetic expression feature alterations and different TCM constitution distribution in NAFLD. Through this method, the study intends to associate the genetic feature with the phenotype of TCM constitution. The results could be applied to assist integrative medicine research in exploring the appropriate personalized approaches for NAFLD.

目的:本研究的主要目的是分析非酒精性脂肪性肝病(NAFLD)的遗传表达特征,分析特定的中医体质分布,揭示NAFLD的代谢特征。材料和方法:为了揭示遗传特征,我们从国家生物技术信息中心(NCBI)的基因表达综合数据库(GEO)中获得了基因表达数据。通过鉴定差异表达基因(DEGs)、相关途径、共表达遗传网络和基因集富集功能来分析NAFLD的遗传数据。同时,我们通过建立的中医体质模型评估了局部NAFLD患者的特定体质分布,并通过回归分析确定了自变量,包括NAFLD的特定体质。结果:对GEO数据集的分析表明,NAFLD中的简单脂肪变性与HOMA胰岛素抵抗(HOMA-IR)密切相关。对GEO数据集的分析显示,NAFLD和正常人群之间的基因表达谱发生了显著变化。在中医体质分析中,我们发现NAFLD的阴阳调和(YYH)和阳虚(YAAC)体质下降,而气滞(QSC)和痰湿(PDC)增加。二元逻辑回归分析表明,除其他代谢参数外,YYH、气虚(QAC)、YYAC和阴虚(YAC)是NAFLD的自变量,YAC是T2D的自变量。多元线性回归分析表明,NAFLD、DM、BMI、腰围、TC、TG、高血压、ALT、AST和YAC是FPG的重要决定因素。结论:本研究提供了一个相对全面的NAFLD脂肪变性代谢谱,通过显著的遗传表达特征改变和NAFLD不同的中医体质分布来揭示。通过这种方法,本研究旨在将遗传特征与中医体质表型联系起来。研究结果可用于协助综合医学研究探索适合NAFLD的个性化方法。
{"title":"The Integrated Bioinformatic Assay of Genetic Expression Features and Analyses of Traditional Chinese Medicine Specific Constitution Reveal Metabolic Characteristics and Targets in Steatosis of Nonalcoholic Fatty Liver Disease.","authors":"Chunping Qiao,&nbsp;Chengying Gu,&nbsp;Song Wen,&nbsp;Yanju He,&nbsp;Sheng Yang,&nbsp;Xinge Feng,&nbsp;Yipeng Zeng","doi":"10.2147/HMER.S428161","DOIUrl":"https://doi.org/10.2147/HMER.S428161","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, our primary aim is to analyze the genetic expression feature and analyze specific Traditional Chinese medicine (TCM) constitution distribution in non-alcoholic fatty liver disease (NAFLD) and reveal the metabolic characteristic of NAFLD.</p><p><strong>Materials and methods: </strong>For revealing genetic features, we obtained the gene expression data from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). The genetic data on NAFLD were analyzed by identifying differentially expressed genes (DEGs), associated pathways, co-expressed genetic networks, and gene set enrichment function. Concurrently, we assessed specific constitution distributions among local NAFLD patients through established TCM constitution models and determined the independent variable, including specific constitution to the NAFLD via the regression analyses.</p><p><strong>Results: </strong>The analyses on GEO datasets showed that simple steatosis in NAFLD is strongly associated with HOMA-insulin resistance (HOMA-IR). Analyses of GEO datasets revealed significantly altered genetic expression profiles between NAFLD and normal populations. For TCM constitution analyses, we demonstrated a decline in yin-yang harmony (YYH) and yang-asthenia (YAAC) constitution, whereas there was an increase in qi-stagnation (QSC) and phlegm-dampness (PDC) in NAFLD. The binary logistic regression analysis indicated that besides other metabolic parameters, YYH, qi asthenia (QAC), YYAC, and yin-asthenia (YAC) were the independent variables of NAFLD, while YAC was the independent variables of T2D. The multilinear regression analyses suggested that NAFLD, DM, BMI, waist, TC, TG, hypertension, ALT, AST, and YAC were the significant determinators of the FPG.</p><p><strong>Conclusion: </strong>This study presents a relatively comprehensive metabolic profile in steatosis of NAFLD, revealed by significant genetic expression feature alterations and different TCM constitution distribution in NAFLD. Through this method, the study intends to associate the genetic feature with the phenotype of TCM constitution. The results could be applied to assist integrative medicine research in exploring the appropriate personalized approaches for NAFLD.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/57/hmer-15-165.PMC10563782.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention. 新冠肺炎死亡的肝损伤和胆道病患者的临床和组织病理学发现:干预的见解和机会。
IF 2.1 Pub Date : 2023-10-04 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S385133
Joseph K Lim, Basile Njei

The COVID-19 pandemic has had a profound impact on global health, necessitating a comprehensive understanding of its diverse manifestations. Cholangiopathy, a condition characterized by biliary dysfunction, has emerged as a significant complication in COVID-19 patients. In this review, we report the epidemiology of COVID-19, describe the hepatotropism of SARS-CoV-2, and present the histopathology of acute liver injury (ALI) in COVID-19. Additionally, we explore the relationship between pre-existing chronic liver disease and COVID-19, shedding light on the increased susceptibility of these individuals to develop cholangiopathy. Through an in-depth analysis of cholangiopathy in COVID-19 patients, we elucidate its clinical manifestations, diagnostic criteria, and underlying pathogenesis involving inflammation, immune dysregulation, and vascular changes. Furthermore, we provide a summary of studies investigating post-COVID-19 cholangiopathy, highlighting the long-term effects and potential management strategies for this condition, and discussing opportunities for intervention, including therapeutic targets, diagnostic advancements, supportive care, and future research needs.

新冠肺炎大流行对全球卫生产生了深远影响,需要全面了解其各种表现。胆管病是一种以胆道功能障碍为特征的疾病,已成为新冠肺炎患者的一种重要并发症。在这篇综述中,我们报道了新冠肺炎的流行病学,描述了SARS-CoV-2的嗜肝性,并介绍了新冠肺炎急性肝损伤(ALI)的组织病理学。此外,我们还探讨了先前存在的慢性肝病与新冠肺炎之间的关系,揭示了这些人患胆管病的易感性增加。通过对新冠肺炎患者胆道病的深入分析,我们阐明了其临床表现、诊断标准和潜在的发病机制,包括炎症、免疫失调和血管变化。此外,我们提供了对COVID-19后胆道病的研究总结,强调了这种疾病的长期影响和潜在管理策略,并讨论了干预的机会,包括治疗目标、诊断进展、支持性护理和未来的研究需求。
{"title":"Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention.","authors":"Joseph K Lim,&nbsp;Basile Njei","doi":"10.2147/HMER.S385133","DOIUrl":"10.2147/HMER.S385133","url":null,"abstract":"<p><p>The COVID-19 pandemic has had a profound impact on global health, necessitating a comprehensive understanding of its diverse manifestations. Cholangiopathy, a condition characterized by biliary dysfunction, has emerged as a significant complication in COVID-19 patients. In this review, we report the epidemiology of COVID-19, describe the hepatotropism of SARS-CoV-2, and present the histopathology of acute liver injury (ALI) in COVID-19. Additionally, we explore the relationship between pre-existing chronic liver disease and COVID-19, shedding light on the increased susceptibility of these individuals to develop cholangiopathy. Through an in-depth analysis of cholangiopathy in COVID-19 patients, we elucidate its clinical manifestations, diagnostic criteria, and underlying pathogenesis involving inflammation, immune dysregulation, and vascular changes. Furthermore, we provide a summary of studies investigating post-COVID-19 cholangiopathy, highlighting the long-term effects and potential management strategies for this condition, and discussing opportunities for intervention, including therapeutic targets, diagnostic advancements, supportive care, and future research needs.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/fa/hmer-15-151.PMC10560482.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41182461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Alcohol Consumption and Addiction on Liver Transplantation Programs in the COVID-19 Era. 新冠肺炎时代饮酒和成瘾对肝移植项目的影响。
IF 2.1 Pub Date : 2023-09-29 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S384070
Richie Manikat, Aijaz Ahmed, Donghee Kim

The coronavirus disease 2019 (COVID-19) pandemic has caused significant shifts in alcohol consumption patterns in the United States, with potential long-term implications for liver transplantation (LT) programs. Alcohol consumption has increased, particularly in women, leading to a rise in alcohol-related liver disease (ALD) and alcohol use disorder. Psychological distress associated with the pandemic may further exacerbate alcohol addiction. ALD is now the most common indication for LT, with higher disease severity and complex clinical presentations, demanding a fundamental transformation in LT programs. Multidisciplinary cooperation among medical specialists, telemedicine, and remote healthcare are essential strategies to address these challenges. However, barriers to telemedicine and costs must be overcome. Curbing alcohol consumption at the societal level and bolstering mental health programs to mitigate healthcare workforce moral injury are recommended to optimize patient care in the post-COVID-19 era. Adequate planning and compassionate management of finite resources will be crucial for the successful continuation of LT programs amidst the concerning trends in alcohol consumption and addiction.

2019冠状病毒病(新冠肺炎)大流行已导致美国酒精消费模式发生重大变化,对肝移植(LT)计划有潜在的长期影响。饮酒量增加,尤其是女性,导致酒精相关肝病(ALD)和酒精使用障碍的增加。与疫情相关的心理困扰可能会进一步加剧酒精成瘾。ALD现在是LT最常见的适应症,具有更高的疾病严重程度和复杂的临床表现,需要对LT项目进行根本性的转变。医学专家、远程医疗和远程医疗之间的多学科合作是应对这些挑战的重要战略。然而,必须克服远程医疗的障碍和成本。建议在社会层面控制饮酒,并加强心理健康计划,以减轻医护人员的道德伤害,从而优化后COVID-19时代的患者护理。在令人担忧的饮酒和成瘾趋势中,对有限资源进行充分的规划和富有同情心的管理对于LT项目的成功延续至关重要。
{"title":"The Impact of Alcohol Consumption and Addiction on Liver Transplantation Programs in the COVID-19 Era.","authors":"Richie Manikat,&nbsp;Aijaz Ahmed,&nbsp;Donghee Kim","doi":"10.2147/HMER.S384070","DOIUrl":"10.2147/HMER.S384070","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has caused significant shifts in alcohol consumption patterns in the United States, with potential long-term implications for liver transplantation (LT) programs. Alcohol consumption has increased, particularly in women, leading to a rise in alcohol-related liver disease (ALD) and alcohol use disorder. Psychological distress associated with the pandemic may further exacerbate alcohol addiction. ALD is now the most common indication for LT, with higher disease severity and complex clinical presentations, demanding a fundamental transformation in LT programs. Multidisciplinary cooperation among medical specialists, telemedicine, and remote healthcare are essential strategies to address these challenges. However, barriers to telemedicine and costs must be overcome. Curbing alcohol consumption at the societal level and bolstering mental health programs to mitigate healthcare workforce moral injury are recommended to optimize patient care in the post-COVID-19 era. Adequate planning and compassionate management of finite resources will be crucial for the successful continuation of LT programs amidst the concerning trends in alcohol consumption and addiction.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/da/hmer-15-141.PMC10546995.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41144556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia. 埃塞俄比亚肝硬化住院患者不适当处方和预测因素的负担。
IF 2.1 Pub Date : 2023-09-25 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S423351
Tirsit Ketsela Zeleke, Zegaye Agmassie Bazezew, Rahel Belete Abebe

Background: Pathophysiological alterations in liver cirrhosis affect how medications are metabolized and eliminated. Therefore, when prescribing medicines for patients with cirrhosis, appropriate prescription of medication is an accepted standard of practice. Since patients with cirrhosis require a complex therapy plan, it necessitates regular reviews of medication utilization. However, no research was conducted in Ethiopia. The aim of this study was to figure out the predictors of inappropriate prescriptions and the pattern of prescription in patients with cirrhosis.

Patients and methods: A cross-sectional study design was carried out at Felege-Hiwot, a specialized and comprehensive referral hospital, from June 30, 2022, to November 30, 2022, in 123 hospitalized patients with cirrhosis. Patients were recruited using a simple random sampling procedure, and data were collected using an interviewer-administered questionnaire. For the purpose of identifying determinants of inappropriate prescription, logistic regression analyses have been carried out and statistical significance was defined by a p-value of less than 0.05 and a 95% confidence range.

Results: The burden of inappropriate prescriptions among patients with cirrhosis was 35.8%. An increased number of medications prescribed (AOR = 4.88 (1.05-22.68)), prescription by a general practitioner (AOR = 3.57 (95% CI 1.07-11.44)), increased level of bilirubin (AOR = 3.54 (95% CI 1.95-6.45)), and decreased level of albumin (AOR = 0.18 (95% CI 0.04-0.72)) were predictors for an inappropriate prescription.

Conclusion: It has been found that there were inappropriate prescriptions among patients with liver cirrhosis. Prescribers should pay close attention to patients who have prescribed with higher number of medications, increased level of bilirubin and decreased level of albumin. Moreover, educational level of prescribers needs to be upgraded in order to adopt evidence-based medication prescriptions and adhere to recommended practices.

背景:肝硬化的病理生理学改变影响药物的代谢和消除。因此,在为肝硬化患者开药时,适当的药物处方是公认的实践标准。由于肝硬化患者需要复杂的治疗计划,因此需要定期审查药物使用情况。然而,埃塞俄比亚没有进行任何研究。本研究的目的是找出肝硬化患者不适当处方的预测因素和处方模式。患者和方法:2022年6月30日至2022年11月30日,在专业综合转诊医院Felege Hiwot对123名肝硬化住院患者进行了横断面研究设计。采用简单的随机抽样程序招募患者,并使用访谈者管理的问卷收集数据。为了确定不合适处方的决定因素,进行了逻辑回归分析,并通过小于0.05的p值和95%的置信区间来定义统计显著性。结果:肝硬化患者的不适当处方负担为35.8%。开药次数增加(AOR=4.88(1.05-2.68)),全科医生开药次数(AOR=3.57(95%CI 1.07-11.44)),胆红素水平增加(AOR=3.54(95%CI 1.95-6.45)),白蛋白水平降低(AOR=0.18(95%CI 0.04-0.72))是不适当处方的预测因素。结论:肝硬化患者存在处方不当的现象。处方医生应密切关注那些开了大量药物、胆红素水平升高和白蛋白水平降低的患者。此外,处方医生的教育水平需要提高,以便采用循证药物处方并坚持推荐的做法。
{"title":"The Burden of Inappropriate Prescriptions and Predictors for Hospitalized Patients with Liver Cirrhosis in Ethiopia.","authors":"Tirsit Ketsela Zeleke,&nbsp;Zegaye Agmassie Bazezew,&nbsp;Rahel Belete Abebe","doi":"10.2147/HMER.S423351","DOIUrl":"https://doi.org/10.2147/HMER.S423351","url":null,"abstract":"<p><strong>Background: </strong>Pathophysiological alterations in liver cirrhosis affect how medications are metabolized and eliminated. Therefore, when prescribing medicines for patients with cirrhosis, appropriate prescription of medication is an accepted standard of practice. Since patients with cirrhosis require a complex therapy plan, it necessitates regular reviews of medication utilization. However, no research was conducted in Ethiopia. The aim of this study was to figure out the predictors of inappropriate prescriptions and the pattern of prescription in patients with cirrhosis.</p><p><strong>Patients and methods: </strong>A cross-sectional study design was carried out at Felege-Hiwot, a specialized and comprehensive referral hospital, from June 30, 2022, to November 30, 2022, in 123 hospitalized patients with cirrhosis. Patients were recruited using a simple random sampling procedure, and data were collected using an interviewer-administered questionnaire. For the purpose of identifying determinants of inappropriate prescription, logistic regression analyses have been carried out and statistical significance was defined by a p-value of less than 0.05 and a 95% confidence range.</p><p><strong>Results: </strong>The burden of inappropriate prescriptions among patients with cirrhosis was 35.8%. An increased number of medications prescribed (AOR = 4.88 (1.05-22.68)), prescription by a general practitioner (AOR = 3.57 (95% CI 1.07-11.44)), increased level of bilirubin (AOR = 3.54 (95% CI 1.95-6.45)), and decreased level of albumin (AOR = 0.18 (95% CI 0.04-0.72)) were predictors for an inappropriate prescription.</p><p><strong>Conclusion: </strong>It has been found that there were inappropriate prescriptions among patients with liver cirrhosis. Prescribers should pay close attention to patients who have prescribed with higher number of medications, increased level of bilirubin and decreased level of albumin. Moreover, educational level of prescribers needs to be upgraded in order to adopt evidence-based medication prescriptions and adhere to recommended practices.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/65/hmer-15-129.PMC10542506.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41133336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases. 巨噬细胞在酒精相关肝病中的致病作用不明。
IF 2.1 Pub Date : 2023-09-21 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S326468
Yeni Ait Ahmed, Fouad Lafdil, Frank Tacke

Alcohol-associated liver disease (ALD) represents a major public health issue worldwide and is a leading etiology of liver cirrhosis. Alcohol-related liver injuries include a range of manifestations including alcoholic hepatitis (AH), simple steatosis, steatohepatitis, hepatic fibrosis, cirrhosis and liver cancer. Liver disease occurs from several pathological disturbances such as the metabolism of ethanol, which generates reactive oxygen species (ROS) in hepatocytes, alterations in the gut microbiota, and the immune response to these changes. A common hallmark of these liver affections is the establishment of an inflammatory environment, and some (broad) anti-inflammatory approaches are used to treat AH (eg, corticosteroids). Macrophages, which represent the main innate immune cells in the liver, respond to a wide variety of (pathogenic) stimuli and adopt a large spectrum of phenotypes. This translates to a diversity of functions including pathogen and debris clearance, recruitment of other immune cells, activation of fibroblasts, or tissue repair. Thus, macrophage populations play a crucial role in the course of ALD, but the underlying mechanisms driving macrophage polarization and their functionality in ALD are complex. In this review, we explore the various populations of hepatic macrophages in alcohol-associated liver disease and the underlying mechanisms driving their polarization. Additionally, we summarize the crosstalk between hepatic macrophages and other hepatic cell types in ALD, in order to support the exploration of targeted therapeutics by modulating macrophage polarization.

酒精相关性肝病(ALD)是世界范围内的一个主要公共卫生问题,也是肝硬化的主要病因。酒精性肝损伤包括一系列表现,包括酒精性肝炎(AH)、单纯性脂肪变性、脂肪性肝炎、肝纤维化、肝硬化和癌症。肝病是由几种病理紊乱引起的,如乙醇的代谢,乙醇在肝细胞中产生活性氧,肠道微生物群的改变,以及对这些变化的免疫反应。这些肝脏疾病的一个常见标志是炎症环境的建立,一些(广泛的)抗炎方法用于治疗AH(如皮质类固醇)。巨噬细胞是肝脏中主要的先天免疫细胞,对各种(致病)刺激有反应,并具有广泛的表型。这转化为多种功能,包括病原体和碎片清除、其他免疫细胞的募集、成纤维细胞的激活或组织修复。因此,巨噬细胞群体在ALD过程中发挥着至关重要的作用,但驱动巨噬细胞极化的潜在机制及其在ALD中的功能是复杂的。在这篇综述中,我们探讨了酒精相关肝病中肝巨噬细胞的不同群体及其极化的潜在机制。此外,我们总结了ALD中肝巨噬细胞和其他肝细胞类型之间的串扰,以支持通过调节巨噬细胞极化来探索靶向治疗方法。
{"title":"Ambiguous Pathogenic Roles of Macrophages in Alcohol-Associated Liver Diseases.","authors":"Yeni Ait Ahmed,&nbsp;Fouad Lafdil,&nbsp;Frank Tacke","doi":"10.2147/HMER.S326468","DOIUrl":"https://doi.org/10.2147/HMER.S326468","url":null,"abstract":"<p><p>Alcohol-associated liver disease (ALD) represents a major public health issue worldwide and is a leading etiology of liver cirrhosis. Alcohol-related liver injuries include a range of manifestations including alcoholic hepatitis (AH), simple steatosis, steatohepatitis, hepatic fibrosis, cirrhosis and liver cancer. Liver disease occurs from several pathological disturbances such as the metabolism of ethanol, which generates reactive oxygen species (ROS) in hepatocytes, alterations in the gut microbiota, and the immune response to these changes. A common hallmark of these liver affections is the establishment of an inflammatory environment, and some (broad) anti-inflammatory approaches are used to treat AH (eg, corticosteroids). Macrophages, which represent the main innate immune cells in the liver, respond to a wide variety of (pathogenic) stimuli and adopt a large spectrum of phenotypes. This translates to a diversity of functions including pathogen and debris clearance, recruitment of other immune cells, activation of fibroblasts, or tissue repair. Thus, macrophage populations play a crucial role in the course of ALD, but the underlying mechanisms driving macrophage polarization and their functionality in ALD are complex. In this review, we explore the various populations of hepatic macrophages in alcohol-associated liver disease and the underlying mechanisms driving their polarization. Additionally, we summarize the crosstalk between hepatic macrophages and other hepatic cell types in ALD, in order to support the exploration of targeted therapeutics by modulating macrophage polarization.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/47/hmer-15-113.PMC10519224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Plants Used for the Management of Hepatitis Over the Past 15 Years in Ethiopia: A Systematic Review. 过去15年来埃塞俄比亚用于肝炎管理的药用植物:系统综述。
IF 2.1 Pub Date : 2023-01-01 DOI: 10.2147/HMER.S402975
Yibeltal Aschale, Bantayehu Addis Tegegne, Wubetu Yihunie

Background: Treatment of human and animal ailments using botanical sources has obtained significant attention in Ethiopia. The compounds available in plants comprise a plentiful source of bioactive ingredients able to treat many complications. The review aimed to present an updated list of plants used for managing hepatitis over the past 15 years in Ethiopia.

Methods: Systematic, comprehensive search was undertaken from electronic databases (PubMed, Google Scholar, Science Direct, and Scopus) between September 01 and October 15, 2022, using standard search terms. Original researches carried out in Ethiopia, written and published in English between January 01/2007 and December 31/2021, and reported hepatitis as a disease treated by medicinal plants were included in the review. Plants beyond the list of Ethiopian and Eritrean floral were excluded. Data were extracted from texts and tables of original papers on a Microsoft Excel. Quality was assessed by applying the Joanna Briggs Institute Critical Appraisal Checklist.

Results: A total of 317 papers were obtained from the database search. After removing duplicates and screening, 15 articles fit the inclusion criteria and selected for final review. Of the 24 plants identified, 35.7% were herbs. Leaf and root (35.7% each) were the predominant plant parts used for remedy preparation. Combined use of leaf and root comprised 10.7%. The families Apocynaceae, Asteraceae, Euphorbiaceae, Cucurbitaceae, and Fabaceae comprise the highest number of plant species. About 89.3% of remedies were administered orally.

Conclusion: The majority of plants belong to herbs and the frequently used plant parts are leaf and roots. Evidence generated from the present review indicated that lots of plants have been used to manage hepatitis. Moreover, the findings could serve as preliminary information to formulate new drugs acting against hepatitis. Therefore, it is desirable for scholars to recognize, document, and keep plants and the associated knowledge appropriately.

背景:在埃塞俄比亚,利用植物资源治疗人类和动物疾病得到了极大的关注。植物中的化合物含有丰富的生物活性成分,能够治疗许多并发症。该综述旨在提供埃塞俄比亚过去15年来用于治疗肝炎的植物的最新清单。方法:在2022年9月1日至10月15日期间,使用标准检索词对电子数据库(PubMed、Google Scholar、Science Direct和Scopus)进行系统、全面的检索。2007年1月1日至2021年12月31日期间在埃塞俄比亚进行的以英文撰写和发表的原始研究报告将肝炎作为一种由药用植物治疗的疾病纳入了审查。埃塞俄比亚和厄立特里亚花卉之外的植物被排除在外。数据在Microsoft Excel中从原始论文的文本和表格中提取。质量通过应用乔安娜布里格斯研究所关键评估清单进行评估。结果:在数据库中检索到论文317篇。在剔除重复和筛选后,15篇文章符合纳入标准,入选最终评审。在鉴定的24种植物中,35.7%为草本植物。叶和根是制备药物的主要植物部位,各占35.7%。叶和根的综合利用占10.7%。夹竹桃科、菊科、大戟科、葫芦科和豆科是数量最多的植物物种。89.3%的药物是口服的。结论:植物以草本植物为主,常用植物部位为叶和根。从本综述中获得的证据表明,许多植物已被用于治疗肝炎。此外,研究结果可为研制抗肝炎新药提供初步信息。因此,学者们需要适当地认识、记录和保存植物及其相关知识。
{"title":"Medicinal Plants Used for the Management of Hepatitis Over the Past 15 Years in Ethiopia: A Systematic Review.","authors":"Yibeltal Aschale,&nbsp;Bantayehu Addis Tegegne,&nbsp;Wubetu Yihunie","doi":"10.2147/HMER.S402975","DOIUrl":"https://doi.org/10.2147/HMER.S402975","url":null,"abstract":"<p><strong>Background: </strong>Treatment of human and animal ailments using botanical sources has obtained significant attention in Ethiopia. The compounds available in plants comprise a plentiful source of bioactive ingredients able to treat many complications. The review aimed to present an updated list of plants used for managing hepatitis over the past 15 years in Ethiopia.</p><p><strong>Methods: </strong>Systematic, comprehensive search was undertaken from electronic databases (PubMed, Google Scholar, Science Direct, and Scopus) between September 01 and October 15, 2022, using standard search terms. Original researches carried out in Ethiopia, written and published in English between January 01/2007 and December 31/2021, and reported hepatitis as a disease treated by medicinal plants were included in the review. Plants beyond the list of Ethiopian and Eritrean floral were excluded. Data were extracted from texts and tables of original papers on a Microsoft Excel. Quality was assessed by applying the Joanna Briggs Institute Critical Appraisal Checklist.</p><p><strong>Results: </strong>A total of 317 papers were obtained from the database search. After removing duplicates and screening, 15 articles fit the inclusion criteria and selected for final review. Of the 24 plants identified, 35.7% were herbs. Leaf and root (35.7% each) were the predominant plant parts used for remedy preparation. Combined use of leaf and root comprised 10.7%. The families Apocynaceae, <i>Asteraceae, Euphorbiaceae</i>, Cucurbitaceae, and Fabaceae comprise the highest number of plant species. About 89.3% of remedies were administered orally.</p><p><strong>Conclusion: </strong>The majority of plants belong to herbs and the frequently used plant parts are leaf and roots. Evidence generated from the present review indicated that lots of plants have been used to manage hepatitis. Moreover, the findings could serve as preliminary information to formulate new drugs acting against hepatitis. Therefore, it is desirable for scholars to recognize, document, and keep plants and the associated knowledge appropriately.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/48/hmer-15-11.PMC10010132.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9179993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients? SARS-CoV2后继发硬化性胆管炎:重症监护患者胆道缺血时使用氯胺酮或病毒特异性胆道偏向性和损伤?
IF 2.1 Pub Date : 2023-01-01 DOI: 10.2147/HMER.S384220
Alessandra Bartoli, Carmela Cursaro, Hajrie Seferi, Pietro Andreone

Purpose: From the beginning of the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV2) pandemic, different cases of a cholangiopathy with features of secondary sclerosing cholangitis in critically ill patients (SSC-CIP) have been reported. Patients developing it are generally recovering from severe Coronavirus disease 19 (COVID-19) and required intensive care unit (ICU) admission and mechanical ventilation. Many of them have been administered with ketamine during their ICU stay. The pathogenesis of this novel disease is still debated, and, since prognosis is poor, efforts are needed in order to better understand it.

Patients and methods: In this review, we focused our attention on COVID-19 SSC clinical, imaging, and histology findings in order to clarify the different pathogenetic options, particularly in regard of the ischemic-direct viral damage and ketamine-related theories, beginning with a recapitulation of SSC-CIP and ketamine-induced cholangiopathy in abusers. The research has been conducted using PubMed and Google Scholar databases. Key-words were "Secondary Sclerosing Cholangiopathy", "SSC-CIP", "Secondary Sclerosing Cholangiopathy in critically ill patients", "Ketamine and cholangiopathy", "Ketamine abusers and liver disease", "Ketamine-related cholangiopathy", "SARS-CoV2 infection and liver disease", "post Covid-19 secondary sclerosing cholangitis", "Covid-19 cholangiopathy".

Results: Many authors, based on the clinical, histological, imaging, and prognostic features of the disease, have pointed out the similarities between post COVID-19 SSC and SSC-CIP; however, peculiar features in the former were not previously observed. Therefore, a direct viral cytopathic action and SARS-CoV2-related coagulopathy are considered the most likely causes. On the other hand, ketamine, with the available data, cannot be surely linked as the main determinant cause of cholangiopathy. Moreover, ketamine-induced cholangitis (KIC) presentation is different from post COVID-19 SSC. Its role as a cofactor precipitating the disease cannot be ruled out.

Conclusion: Post COVID-19 SSC is a rare clinical entity following severe COVID-19 disease. The most accepted theory is that a sum of different insults determines the disease: biliary ischemia, direct viral damage, toxic bile, possibly worsened by ketamine and hyperinflammation due to the cytokine storm. Given the severe prognosis of the disease, with persistent cholangiopathy, organ failure, and orthotopic liver transplantation (OLT), further study on this novel clinical entity is needed.

目的:从SARS-CoV2大流行开始,重症患者(SSC-CIP)中出现了不同的以继发性硬化性胆管炎为特征的胆管病病例。发生这种情况的患者通常是从COVID-19 (COVID-19)重症监护病房(ICU)康复并需要机械通气。他们中的许多人在重症监护病房期间服用氯胺酮。这种新型疾病的发病机制仍有争议,由于预后不佳,需要努力更好地了解它。患者和方法:在本综述中,我们将重点放在COVID-19 SSC的临床、影像学和组织学发现上,以阐明不同的病因选择,特别是关于缺血性直接病毒损伤和氯胺酮相关的理论,首先概述SSC- cip和氯胺酮诱导的滥用者胆管病。这项研究是通过PubMed和Google Scholar数据库进行的。关键词是“继发性硬化性胆管病”、“SSC-CIP”、“危重患者继发性硬化性胆管病”、“氯胺酮与胆管病”、“氯胺酮滥用者与肝脏疾病”、“氯胺酮相关性胆管病”、“SARS-CoV2感染与肝脏疾病”、“Covid-19后继发性硬化性胆管炎”、“Covid-19胆管病”。结果:许多作者根据疾病的临床、组织学、影像学和预后特征,指出了COVID-19后SSC与SSC- cip的相似之处;然而,前者的特殊特征以前没有被观察到。因此,直接的病毒细胞病变作用和sars - cov2相关的凝血功能障碍被认为是最可能的原因。另一方面,根据现有数据,氯胺酮不能肯定地与胆管病的主要决定性原因联系起来。此外,氯胺酮诱导的胆管炎(KIC)的表现与COVID-19后SSC不同。不能排除它作为促成疾病的辅助因素的作用。结论:COVID-19后SSC是一种罕见的重症病例。最被接受的理论是,不同的损害决定了疾病:胆道缺血,直接病毒损伤,胆汁中毒,可能因氯胺酮和细胞因子风暴引起的高炎症而恶化。鉴于该病预后严重,伴有持续性胆管病变、器官衰竭和原位肝移植(OLT),需要进一步研究这一新的临床实体。
{"title":"Secondary Sclerosing Cholangitis After SARS-CoV2: ICU Ketamine Use or Virus-Specific Biliary Tropism and Injury in the Context of Biliary Ischemia in Critically Ill Patients?","authors":"Alessandra Bartoli,&nbsp;Carmela Cursaro,&nbsp;Hajrie Seferi,&nbsp;Pietro Andreone","doi":"10.2147/HMER.S384220","DOIUrl":"https://doi.org/10.2147/HMER.S384220","url":null,"abstract":"<p><strong>Purpose: </strong>From the beginning of the Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV2) pandemic, different cases of a cholangiopathy with features of secondary sclerosing cholangitis in critically ill patients (SSC-CIP) have been reported. Patients developing it are generally recovering from severe Coronavirus disease 19 (COVID-19) and required intensive care unit (ICU) admission and mechanical ventilation. Many of them have been administered with ketamine during their ICU stay. The pathogenesis of this novel disease is still debated, and, since prognosis is poor, efforts are needed in order to better understand it.</p><p><strong>Patients and methods: </strong>In this review, we focused our attention on COVID-19 SSC clinical, imaging, and histology findings in order to clarify the different pathogenetic options, particularly in regard of the ischemic-direct viral damage and ketamine-related theories, beginning with a recapitulation of SSC-CIP and ketamine-induced cholangiopathy in abusers. The research has been conducted using PubMed and Google Scholar databases. Key-words were \"Secondary Sclerosing Cholangiopathy\", \"SSC-CIP\", \"Secondary Sclerosing Cholangiopathy in critically ill patients\", \"Ketamine and cholangiopathy\", \"Ketamine abusers and liver disease\", \"Ketamine-related cholangiopathy\", \"SARS-CoV2 infection and liver disease\", \"post Covid-19 secondary sclerosing cholangitis\", \"Covid-19 cholangiopathy\".</p><p><strong>Results: </strong>Many authors, based on the clinical, histological, imaging, and prognostic features of the disease, have pointed out the similarities between post COVID-19 SSC and SSC-CIP; however, peculiar features in the former were not previously observed. Therefore, a direct viral cytopathic action and SARS-CoV2-related coagulopathy are considered the most likely causes. On the other hand, ketamine, with the available data, cannot be surely linked as the main determinant cause of cholangiopathy. Moreover, ketamine-induced cholangitis (KIC) presentation is different from post COVID-19 SSC. Its role as a cofactor precipitating the disease cannot be ruled out.</p><p><strong>Conclusion: </strong>Post COVID-19 SSC is a rare clinical entity following severe COVID-19 disease. The most accepted theory is that a sum of different insults determines the disease: biliary ischemia, direct viral damage, toxic bile, possibly worsened by ketamine and hyperinflammation due to the cytokine storm. Given the severe prognosis of the disease, with persistent cholangiopathy, organ failure, and orthotopic liver transplantation (OLT), further study on this novel clinical entity is needed.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/9f/hmer-15-93.PMC10404108.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9955815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Hepatic Medicine : Evidence and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1